Entries Tagged 'futures market' ↓

www.informedtrades.com The 3rd lesson in a series on charting patterns which looks at the head and shoulders pattern and how traders use this in the stock market, forex market, and futures market.

A look at how the price of oil may be dragging down the recent attempts at a stock market rally, a snapshot of the much hyped (and possibly valid) “Hindenberg Omen” portending a possible stock market crash. Produced byy Jonah S. Ford on August 20th, 2010

French Market Modestly Down
(RTTNews) – The French market is modestly down in afternoon trading Monday, following a strong rally last week. Utilities were under pressure, while banks were mostly higher.

Read more on INO News

Market Snapshot: U.S. stock market looks for next catalyst
The days ahead could be relatively quiet one for the U.S. stock market after an intense week that had the Federal Reserve offering another economic jolt and Republicans taking control of the U.S. House of Representatives.

Read more on Market Watch

GlobalData’s report, “HIV/AIDS – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was worth $12 billion in 2009. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has however succeeded in achieving near zero levels of HIV in infected people. Increased uptake of HAART and increasing awareness (which leads to increased treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 250 molecules currently in development for various disease segments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

- Annualized global HIV/AIDS market revenues data from 2001 to 2009, forecast for seven years to 2016.
– Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
– Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include HIV vaccines, Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), CCR5 receptor antagonists, HIV integrase inhibitors, Nucleoside analogues, Viral entry inhibitors, Maturation inhibitors and Fusion Inhibitors.
– Analysis of the current and future market competition in the global HIV/AIDS market. The key market players covered Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco
– Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
– The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future HIV/AIDS market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
– Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global HIV/AIDS market.
– Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global HIV/AIDS market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
– What’s the next big thing in the global HIV/AIDS market landscape? – Identify, understand and capitalize.

TABLE OF CONTENTS

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 HIV/AIDS Market: Market Characterization 6
2.1 Introduction 6
2.2 Disease Overview 7
2.3 HIV/AIDS Market Size 8
2.4 HIV/AIDS Market Forecast and CAGR 9
2.5 Drivers and Barriers for the HIV/AIDS Market 11
2.5.1 Drivers for the HIV/AIDS Market 11
2.5.2 Barriers for the HIV/AIDS Market 13
2.6 Opportunity and Unmet Need 15
2.7 Key Takeaway 17

3 HIV/AIDS Market: Competitive Assessment 18
3.1 Overview 18
3.2 Strategic Competitor Assessment 18
3.3 Product Profiles of the Major Marketed Products in the HIV/AIDS Market 19
3.3.1 Truvada (emtricitabine/tenofovir disoproxil fumarate) 19
3.3.2 Atripla (Efavirenz, Emtricitabine, and Tenofovir) 20
3.3.3 Kaletra (Lopinavir/Ritonavir) 21
3.3.4 Reyataz (Atazanavir sulfate) 22
3.3.5 Sustiva (Efavirenz) 23
3.4 Key Takeaway 25

4 HIV/AIDS Market: Pipeline Assessment 26
4.1 Overview 26
4.2 Strategic Pipeline Assessment 26
4.2.1 Technology Trends Analytic Framework 26
4.3 HIV/AIDS Therapeutics – Promising Drugs under Clinical Development 27
4.4 Molecule Profile for Promising Drugs under Clinical Development 28
4.4.1 Rilpivirine hydrochloride (TMC278) 28
4.4.2 Elvitegravir 29
4.4.3 Apricitabine (ATC) 30
4.4.4 Racivir 31
4.4.5 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) 31
4.5 HIV/AIDS Therapeutics Market – Clinical Pipeline by Mechanism of Action 33
4.6 HIV/AIDS Pipeline – Major Different Classes of Drugs Description 33
4.6.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 33
4.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 34
4.6.3 Protease Inhibitors (PIs) 34
4.6.4 Viral Fusion (or Entry) Inhibitors 34
4.6.5 HIV Integrase Strand Transfer Inhibitors 34
4.6.6 Multi-class Combination Products 34
4.6.7 CCR5 Receptor Antagonist 35
4.7 HIV/AIDS Pipeline – Pipeline by Clinical Phases of Development 36
4.7.1 HIV/AIDS Therapeutics – Phase III Clinical Pipeline 36
4.7.2 HIV/AIDS Therapeutics – Phase II Clinical Pipeline 37
4.7.3 HIV/AIDS Therapeutics – Phase I Clinical Pipeline 39
4.7.4 HIV/AIDS Therapeutics – Preclinical Pipeline 41
4.7.5 HIV/AIDS Therapeutics – Early Development Pipeline 42
4.7.6 Discontinued / Suspended Drugs for HIV/AIDS 43
4.8 Key Takeaway 44

5 HIV/AIDS Market: Implications for Future Market Competition 45

6 HIV/AIDS Market: Future Players in the HIV/AIDS Market 47
6.1 Introduction 47
6.2 Gilead Sciences, Inc 47
6.2.1 Company Overview 47
6.2.2 Financial Performance 47
6.2.3 Business Description 48
6.2.4 Viral Infections Portfolio 48
6.2.5 HIV/AIDS Portfolio 49
6.3 Tibotec Pharmaceuticals Ltd 51
6.3.1 Company Overview 51
6.3.2 Viral Infections Portfolio 51
6.3.3 HIV/AIDS Product Portfolio 51
6.4 Avexa Limited 52
6.4.1 Company Overview 52
6.4.2 Financial Performance 53
6.4.3 Business Description 53
6.4.4 Viral Infections Portfolio 53
6.4.5 HIV/AIDS Product Portfolio 54
6.5 Pharmasset, Inc 54
6.5.1 Company Overview 54
6.5.2 Financial Performance 55
6.5.3 Viral Infections Portfolio 55
6.5.4 HIV/AIDS Product Portfolio 55
6.6 Achillion Pharmaceuticals, Inc 56
6.6.1 Company Overview 56
6.6.2 Financial Performance 56
6.6.3 Business Overview 56
6.6.4 Viral Infections Portfolio 57
6.6.5 HIV/AIDS Product Portfolio 57
6.7 Incyte Corporation 57
6.7.1 Company Overview 57
6.7.2 Financial Performance 58
6.7.3 Business Description 58
6.7.4 Viral Infections Portfolio 58
6.7.5 HIV/AIDS Product Portfolio 58
6.8 Myriad Pharmaceuticals, Inc 59
6.8.1 Company Overview 59
6.8.2 Financial Performance 59
6.8.3 HIV Portfolio 59
6.8.4 HIV/AIDS Product Portfolio 59

7 HIV/AIDS Market: Appendix 60
7.1 Market Definition 60
7.2 Abbreviations 60
7.3 Research Methodology 62
7.3.1 Coverage 62
7.3.2 Secondary Research 63
7.3.3 Forecasting 63
7.3.4 Primary Research 66
7.3.5 Expert Panels 66
7.4 Contact Us 66
7.5 Disclaimer 66
7.6 Sources 67

The Blog Entry that Accompanies this Vlog is at: investorandtrader.blogspot.com My Daily Blog is at: investorandtrader.blogspot.com My channel at BlogTV is: www.blogtv.com There are other strategies that what I list in this video. They are applicable in any market. Be it the Forex markets, daytrading, the stock market, or the commodity futures market. But I urge you to look up different money management strategies, and pick on the fits YOUR risk tolerance (not other peoples risk tolerance, or my risk tolerance) NOTE: This is not an investment or trading recommendation. The losses in trading can be very real, and depending on the investment vehicle, can exceed your initial investment. I am not a licensed trading or investment adviser, or financial planner. But I do have 12 years of experience in trading and investing in these markets. The Challenge accounts are run for the education of other traders who should make their own decisions based off their own research and risk tolerance. Included Music is by Paul Young. A personal friend and is not a part of any music license, recording label, etc

Stock futures jump a day after Fed meeting
Stock futures are rising sharply the day after the Federal Reserve announced a $600 billion plan to stimulate the economy.

Read more on AP via Yahoo! Finance

CNBC Interview with a Intrade user 8.25.2008

GlobalData’s report, “Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global  (ED) therapeutics market. The report identifies the key trends shaping and driving the ED market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ED therapeutics sector. GlobalData’s analysis revealed that the market grew at a CAGR of 9.8% from 2001 to 2009. The growth rate was moderate due lack of ED awareness and reluctance among male general population to discuss their sexual problem. With the patent expiry of a key product, in 2012, the market is expected to decline after 2011, resulting in a CAGR of 4% from 2009 to 2016.

GlobalData’s analysis showed that the ED pipeline is weak. The products in the ED pipeline comprises of me-too class. Some of the promising me-too class drugs/molecules are likely to get approval in coming years which are in phase III trials. One of the promising molecule include Avanafil , which is unlikely to have much impact as market has high competition among similar products and generic erosion after 2012 due to patent expiry of  (citrate).

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

Annualized global ED therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include FKBP12 binder, serotonin and dopamine enhancer, PDE-5 inhibitor, and Alpha1A-adrenoreceptors antagonist.
Analysis of the current and future market competition in the global ED therapeutics market. Key market players covered are VIVUS, Inc., and Rexahn Pharmaceuticals, Inc.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with ED.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global  market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global  market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global  market landscape? – Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 4
1.2 List of Figures 4

2 : Market Characterization 5

2.1 Overview 5
2.2  Market Size 5
2.3  Market Forecast and CAGR 6
2.4 Drivers and Barriers for the  Market 7 2.4.1 Drivers of the  Market 7
2.4.2 Barriers for the  Market 8

2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9

3 Erectile Dysfucntion: Competitive Assessment 10

3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in the E Market 11 3.3.1  ( citrate) 11
3.3.2 12
3.3.3 (verdenafil HCL) 14
3.3.4 Caverject (Alprostadil) 15
3.3.5 Muse (alprostadil) 16

3.4 Key Takeaway 18

4 Erectile Dysfucntion: Pipeline Assessment 19

4.1 Overview 19
4.2 Strategic Pipeline Assessment 19 4.2.1 Technology Trends Analytical Framework 19

4.3  Therapeutics – Promising Drugs under Clinical Development 20
4.4 Drugs under Clinical Development 21 4.4.1 Avanafil 21
4.4.2 Zoraxel 22

4.5  Therapeutics Market – Clinical Pipeline by Mechanism of Action 23
4.6 ED Pipeline – Pipeline by Clinical Phases of Development 23 4.6.1  Therapeutics – Phase III Clinical Pipeline 24
4.6.2  Therapeutics – Phase II Clinical Pipeline 24
4.6.3  Therapeutics – Phase I Clinical Pipeline 24

4.7 Discontinued / Suspended Drugs for  24
4.8 Key Takeaway 24

5  Market: Implications for Future Market Competition 25
6  Market: Future Players in the  Market 26

6.1 Introduction 26
6.2 VIVUS, Inc. 26 6.2.1 Overview 26
6.2.2 Business Description 27
6.2.3 Sexual Dysfunction Portfolio 27
6.2.4  Product Portfolio 28

6.3 Rexahn Pharmaceuticals, Inc. 29 6.3.1 Overview 29
6.3.2 Sexual Dysfunction Portfolio 29
6.3.3 ED Product Portfolio 29

7 : Appendix 31

7.1 Definitions 31
7.2 Abbreviations 31
7.3 Research Methodology 31 7.3.1 Coverage 32
7.3.2 Secondary Research 32
7.3.3 Forecasting 33
7.3.4 Primary Research 36
7.3.5 Expert Panels 36

7.4 Contact Us 36
7.5 Disclaimer 36
7.6 Sources 37

My Daily Blog is at: investorandtrader.blogspot.com We’ve been discussing commodity futures. We learned what a commodity is. We learned that commodities are traded in contracts, and those contracts have specific sizes, and contract months. We talked about leverage and lock-limits. Now let’s talk the nature of the Commodity Futures Market …NOTE: This is not an investment or trading recommendation. The losses in trading can be very real, and depending on the investment vehicle, can exceed your initial investment. I am not a licensed trading or investment adviser, or financial planner. But I do have 12 years of experience in trading and investing in these markets. The Challenge accounts are run for the education of other traders who should make their own decisions based off their own research.